AIFF News & Events

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.TECH PANEL:President Trump has named MetaCEO Mark Zuckerberg, OracleExecutive Chairman Larry Ellison, NvidiaCEO Jensen Huang, and others to the Council of Advisors on Science and Technology, co-chaired by David Sacks, The Wall Street Journal's Annie Linksey and Alex Leary. The President's Council of Advisors on Science and Technology will advise on AI policy and emerging tech issues. "The United States has the opportunity to lead the world in AI," said Zuckerberg in a statement to The Wall Street Journal. "I'm honored to join the President's council and work with other industry leaders to help make this happen."AIRPORT MESS:President Donald Trumpvia Truth Social that, "Blame the Democrats for the Airport's mess. They want our Country to do badly. They want our Country to fail. They broke the already signed Bill because they want to take care of Criminals who enter our Country illegally, rather than American citizens. Thank you to our great ICE Patriots for helping. It makes a big difference. I may call up the National Guard for more help. President DJT." Publicly traded companies in the space include Alaska Air, American Airlines, Delta Air Lines, Frontier Group, JetBlue, Southwest, Sun Country Airlinesand United Airlines.AGENTIC OPERATING SYSTEM:Salesforceannounced the deployment of a new agentic operating system to simplify incident response and improve Veteran care across its more than 150 Department of Veterans Affairs, VA, medical and outpatient centers. By combining Salesforce's real-time data insights, integrated service, and complaint healthcare capabilities into a single, AI-powered operating system in Slack, the VHA is transitioning from static reporting to automated problem-solving that eliminates administrative silos and accelerates front-line Veteran care. This strategy enables the VHA to cut costs, streamline facility operations, and simplify services across facilities nationwide.DEPARTMENT OF WAR PARTNERSHIP:Firefly Neuroscienceannounced a partnership with the Department of War to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder and/or Traumatic Brain Injury. The genesis of this public-private brain health partnership was initial work by the founders of Evoke Neuroscience with the U.S. Naval Medical Center Camp Lejeune Family Medicine Residency program. Specific details of the partnership and related programs remain confidential in accordance with applicable agreements.GOVERNMENT CONTRACTS:Emergent BioSolutionsannounced it has secured a contract award valued at approximately $54M to deliver CNJ-016 to the Administration for Strategic Preparedness and Response, or ASPR, part of the U. S. Department of Health and Human Services, or HHS, for smallpox preparedness. ASPR exercised an option from its existing 10-year contract for additional doses of VIGIV, a treatment for complications due to smallpox vaccination. In addition, Emergent has secured new incremental orders with an international government partner valued at $6.6M. This represents product orders for ACAM2000 within Emergent's medical countermeasures portfolio and will support the partner's smallpox biodefense strategy. These orders stem from a recurring international customer and demonstrate the importance of threat preparedness around the world.

Firefly Neuroscience announced a partnership with the Department of War to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder and/or Traumatic Brain Injury. The genesis of this public-private brain health partnership was initial work by the founders of Evoke Neuroscience with the U.S. Naval Medical Center Camp Lejeune Family Medicine Residency program. Specific details of the partnership and related programs remain confidential in accordance with applicable agreements.

Firefly Neuroscience announced the advancement of research using Resting EEG/Cognitive EEG brain scans collected on its FDA-510(k)-cleared Evoke System to potentially distinguish between the three main subtypes of attention-deficit/hyperactivity disorder: hyperactive and impulsive, inattentive, and combined. Today, a diagnosis of adult ADHD is based upon meeting the following general symptoms-based criteria: symptoms should be present in two or more settings, such as home, work or school; symptoms should clearly interfere with or reduce the functioning of a person in social, work, or school-related activities; symptoms experienced cannot be better explained by another mental health condition, such as depression or anxiety; and symptoms should not only occur during the course of a psychotic disorder like schizophrenia. In addition, healthcare professionals typically use the Diagnostic and Statistical Manual of Mental Disorders to distinguish between the three types of ADHD. According to the DSM-5, adult ADHD may be diagnosed in the following cases: hyperactive and impulsive type ADHD - at least five symptoms of hyperactivity and impulsivity for more than six months without meeting the diagnostic criteria for inattentive behavior; inattentive type ADHD - at least five symptoms of inattention for more than six months without meeting the diagnostic criteria for hyperactive or impulsive behavior; and, combined type ADHD - at least five symptoms of hyperactivity and impulsivity and at least five symptoms of inattention for more than 6 months. Gil Issachar, CTO, said, "While there has been significant progress made in the treatment of ADHD over the years, there is no question that significant unmet need remains, particularly after a general diagnosis of the disorder has been made. For example, some types of ADHD respond well to stimulants, while others don't and neurofeedback therapy may be recommended instead.5 Firefly's EEG/ERP platform can leverage subtype-specific biomarker profiles to inform personalized treatment recommendations, potentially improving outcomes for the millions currently on generalized ADHD treatment plans. We believe that the technology also opens the door to ongoing treatment monitoring - allowing clinicians to objectively track whether an intervention is working at the neurological level."

Firefly Neuroscience announces a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes. Through its acquisition of Evoke Neuroscience and the successful execution of its key internal growth initiatives, Firefly ended 2025 partnered with 99 commercial users who completed a total of more than 10,800 EEG/ERP brain scans. The year-over-year increases in partner sites and EEG/ERP clinical assessments represent growth of 1,880% and 3,227%, respectively, since the end of 2024.